Cargando…

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF

BACKGROUND: Neprilysin is a transmembrane endopeptidase involved in the breakdown of a variety of vasoactive peptides and serves as a therapeutic target in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate the relationship of circulating neprilysin with neurohumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prausmüller, Suriya, Arfsten, Henrike, Spinka, Georg, Freitag, Claudia, Bartko, Philipp E., Goliasch, Georg, Strunk, Guido, Pavo, Noemi, Hülsmann, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428996/ https://www.ncbi.nlm.nih.gov/pubmed/32427034 http://dx.doi.org/10.1161/JAHA.119.015071

Ejemplares similares

Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic
por: Han, Emilie, et al.
Publicado: (2023)

Relevance of Neutrophil Neprilysin in Heart Failure
por: Prausmüller, Suriya, et al.
Publicado: (2021)

Neprilysin inhibition does not alter dynamic of proenkephalin‐A 119‐159 and pro‐substance P in heart failure
por: Arfsten, Henrike, et al.
Publicado: (2021)

Increased concentrations of bioactive adrenomedullin subsequently to angiotensin‐receptor/neprilysin‐inhibitor treatment in chronic systolic heart failure
por: Arfsten, Henrike, et al.
Publicado: (2020)

Neprilysin as a Biomarker: Challenges and Opportunities
por: Pavo, Noemi, et al.
Publicado: (2020)

Circulating dipeptidyl peptidase (cDPP3)—A marker for end‐stage heart failure?
por: Pavo, Noemi, et al.
Publicado: (2022)

Neutrophil Activation/Maturation Markers in Chronic Heart Failure with Reduced Ejection Fraction
por: Prausmüller, Suriya, et al.
Publicado: (2022)

Malnutrition outweighs the effect of the obesity paradox
por: Prausmüller, Suriya, et al.
Publicado: (2022)

Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus
por: Prausmüller, Suriya, et al.
Publicado: (2021)

Neprilysin in HFrEF: Differential Regulation of Tissue Versus Circulating Neprilysin
por: Chen, Horng H., et al.
Publicado: (2020)

Secondary mitral regurgitation—Insights from microRNA assessment
por: Spinka, Georg, et al.
Publicado: (2020)

Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study
por: Bartko, Philipp E, et al.
Publicado: (2021)

The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients
por: Pavo, Noemi, et al.
Publicado: (2019)

Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure
por: Pavo, Noemi, et al.
Publicado: (2019)

An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation
por: Spinka, Georg, et al.
Publicado: (2020)

Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer
por: Arfsten, Henrike, et al.
Publicado: (2021)

The inflammation‐based modified Glasgow prognostic score is associated with survival in stable heart failure patients
por: Cho, Anna, et al.
Publicado: (2020)

Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
por: Spannbauer, Andreas, et al.
Publicado: (2019)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure
por: Arfsten, Henrike, et al.
Publicado: (2019)

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Mortality and Morbidity in HFrEF, HFmrEF, and HFpEF Patients with Diabetes in the Middle East
por: Al-Jarallah, Mohammed, et al.
Publicado: (2020)

A horse of a different colour: distinct mechanisms of HFpEF and HFrEF
por: Louch, William E.
Publicado: (2020)

Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study
por: Anker, Markus S., et al.
Publicado: (2020)

GDF‐15 in solid vs non‐solid treatment‐naïve malignancies
por: Arfsten, Henrike, et al.
Publicado: (2019)

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)

Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF
por: Sherwood, Andrew, et al.
Publicado: (2023)

Corrigendum to: Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
Publicado: (2023)

Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF
por: Ahmeti, Artan, et al.
Publicado: (2017)

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
por: Kristensen, Søren L., et al.
Publicado: (2017)

Myocardial phenotypes and dysfunction in HFpEF and HFrEF assessed by echocardiography and cardiac magnetic resonance
por: Berlot, Bostjan, et al.
Publicado: (2019)

Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy
por: Li, Zheng, et al.
Publicado: (2023)

Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?
por: Kerr, Brian, et al.
Publicado: (2021)

FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF
por: Benes, Jan, et al.
Publicado: (2023)

The vasculature in HFpEF vs HFrEF: differences in contractile protein expression produce distinct phenotypes
por: Lyle, Melissa A., et al.
Publicado: (2019)

Ubiquitin‐proteasome‐system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF
por: Adams, Volker, et al.
Publicado: (2021)

Circulating Relaxin-1 Level Is a Surrogate Marker of Myocardial Fibrosis in HFrEF
por: Simon, Judit, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2skh4hr8ekunhrikijsfk011os